Axsome Therapeutics (AXSM) Q2 2026 earnings review
AUVELITY Surges on Label Expansion, But SG&A and SYMBRAVO Pressures Mount
Axsome delivered robust 46% YoY revenue growth, propelled entirely by the continued dominance of AUVELITY and its newly launched indication for Alzheimer's disease agitation (ADA). However, massive commercial investments to support this launch caused SG&A to explode 60% YoY, keeping the company deeply unprofitable with a $51.3M net loss. While early ADA prescription trends are highly encouraging, the glaring red flag this quarter is SYMBRAVO: despite prescription volume growing sequentially, its net revenue collapsed, signaling severe gross-to-net discount or inventory issues.
🐂 Bull Case
AUVELITY's June 2026 launch in ADA is already yielding results. New-to-brand prescriptions for patients aged 65+ accelerated 126% in just the first eight weeks, validating management's aggressive sales force expansion to 630 reps.
The FDA accepted the NDA for AXS-12 in narcolepsy with a May 2027 PDUFA date, and multiple pivotal trials (FOCUS-2/3 for ADHD, AXS-05 for smoking cessation) are actively initiating, creating a clear path to a multi-product CNS franchise.
🐻 Bear Case
Despite a 30% sequential increase in prescriptions, SYMBRAVO net sales reversed sharply, falling nearly 44% from $4.1M in Q1 to $2.3M in Q2. This implies massive gross-to-net leakage and casts doubt on the migraine commercial strategy.
Operating leverage is deteriorating. While revenue grew by $68.4M YoY, SG&A expenses grew by $77.8M. The company continues to burn cash despite generating over $800M in annualized revenue.
⚖️ Verdict: ⚪
Neutral. The AUVELITY ADA launch is a massive win that secures the company's long-term top-line trajectory, but the sheer cost of commercialization and the alarming SYMBRAVO revenue breakdown prevent a purely bullish outlook.
Key Themes
AUVELITY's Second Act: Alzheimer's Agitation
The June 2026 label expansion into Alzheimer's disease agitation (ADA) is accelerating AUVELITY's growth curve. Total prescriptions rose 34% YoY to 266,000, and overall new-to-brand prescriptions increased 26% sequentially. The 126% spike in starts among patients 65+ proves the expanded 630-person sales force is successfully penetrating the geriatric and long-term care markets.
SYMBRAVO Revenue Decouples from Prescriptions
A severe red flag has emerged in the migraine portfolio. SYMBRAVO's trajectory is reversing abruptly. While total prescriptions written grew 30% sequentially to 23,500, net product sales crashed from $4.1M in Q1 to just $2.3M in Q2. This extreme divergence indicates that Axsome is subsidizing nearly all the volume growth through co-pay cards, free samples, or facing adverse inventory destocking dynamics. High gross-to-net (GTN) discounts are crushing actual revenue realization.
Commercial Expense Cannibalizing Profitability
Axsome's 'growth-first' strategy is coming at an immense cost. SG&A hit an all-time high of $208.1M, accelerating 60% YoY. The aggressive build-out of the primary care and ADA sales forces is preventing the company from achieving operating leverage. Total operating expenses for the quarter reached $268.0M against revenues of $218.4M, resulting in a stable but sustained ~$50M net loss.
SUNOSI Providing Stable Baseline Cash Flow
Amidst the launch volatility of the other assets, SUNOSI remains a remarkably consistent grower. Revenue grew 20% YoY to $35.8M, supported by a 14% increase in prescriptions to ~61,000. Payer coverage across all channels sits at a healthy 82%, making it a reliable, high-margin anchor for the company.
MoSEIC Technology Validates Broader Pipeline
Axsome continues to leverage its MoSEIC rapid absorption technology across a massive 150M+ patient total addressable market. The pipeline is expanding rapidly with Phase 3 initiations (FOCUS-2 and FOCUS-3 for pediatric ADHD using solriamfetol) and the upcoming pivotal Phase 2/3 trial for AXS-05 in smoking cessation. The clinical validation of these first-in-class mechanisms reduces overall portfolio risk.
Other KPIs
Decelerating. R&D actually fell 7% YoY (from $49.5M in 25Q2), reflecting the completion of heavy costs related to AXS-05 and AXS-14, even as new trials initiate. This demonstrates management is shifting capital allocation heavily toward commercialization rather than early-stage discovery.
Stable. Down only slightly from $322.9M at the end of FY25. The company drew down heavily on stock-based compensation ($27.1M in Q2) to manage actual cash burn, allowing them to maintain a runway that management believes will last until cash flow positivity.
Guidance
Stable. Management declined to give explicit revenue or EPS guidance (as they have in previous quarters), reiterating instead that the $319.9M cash balance will bridge the gap to self-sustainability based on the current operating plan. Given the $50M quarterly burn rate, they have roughly 6 quarters of runway assuming no improvement in cash flow.
Key Questions
SYMBRAVO Gross-to-Net Crisis
Prescriptions for SYMBRAVO grew 30% sequentially, but revenue dropped 44%. What is the exact gross-to-net discount currently being applied, and when do you expect the conversion of free or co-pay supported scripts into fully reimbursed commercial claims?
Medicare Part D Mix Shift
With the Alzheimer's agitation launch driving a surge in 65+ patient starts, how is the heavier mix of Medicare Part D volume impacting AUVELITY's blended gross-to-net realization?
SG&A Plateau
SG&A exceeded $208M this quarter following the sales force expansion. Have we reached the peak quarterly commercial spend for the current portfolio, or should we expect continued sequential SG&A increases through the rest of the year?